Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Lin J, Gumuscu B, Lerman N, Soulières D (2025)
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
Eur J Cancer, 221, 115395 (in press)
DOI 10.1016/j.ejca.2025.115395, PubMed 40262400

Grønberg BH, Killingberg KT, Fløtten Ø, Bjaanæs MM, Brustugun OT, Madebo T, Langer SW, Risumlund SL, Schytte T, Helbekkmo N, Neumann K, Yksnøy Ø, Engleson J, Fluge S, Naustdal T, Giske LE, Nyman J, Tsakonas G, Halvorsen TO (2025)
High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial
J Thorac Oncol (in press)
DOI 10.1016/j.jtho.2025.04.007, PubMed 40258573

Eriksen JG, Maare C, Johansen J, Primdahl H, Bratland Å, Kristensen CA, Andersen M, Alsner J, Overgaard J, DAHANCA (2025)
DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck
Radiother Oncol, 110899 (in press)
DOI 10.1016/j.radonc.2025.110899, PubMed 40258418